

AMENDMENTS TO THE CLAIMS:

Claims 1, 2, 9, 17 and 19-21 are amended herein. Claim 28 is added herein. This listing of claims will replace all prior versions, and listings of claims, in the application.

LISTING OF CLAIMS:

1. (Currently amended) A method for destroying or impairing target cells that comprise a lesion in the vascular system in a mammalian ~~subject~~ subject, comprising:
administering to the subject a therapeutically effective amount of a photosensitizing agent, wherein ~~said~~ the photosensitizing agent is conjugated to a ligand that selectively binds to a receptor on target cells of the lesion; and

irradiating at least a portion of the subject with light at a wavelength absorbed by ~~said~~ the photosensitizing agent, wherein; ~~said~~

the light is provided by a light source that is external to the intact body of the subject; ~~and wherein said~~ the irradiation is at a relatively low fluence rate that results in the activation of ~~said~~ the photosensitizing agent; and ~~wherein said~~

the photosensitizing agent is cleared from the skin and subcutaneous tissues of the subject prior to said irradiation.

2. (Currently amended) A method for destroying or impairing target cells that comprise a lesion in the arterial vascular system in a mammalian ~~subject~~ subject, comprising:

administering to the subject a therapeutically effective amount of a first conjugate comprising a first member of a ligand-receptor binding pair conjugated to an antibody or antibody fragment, wherein ~~said~~ the antibody or antibody fragment selectively binds to a target cell or target tissue antigen;

administering to the subject a therapeutically effective amount of a second conjugate comprising a second member of the ligand-receptor binding pair conjugated to a photosensitizing agent or photosensitizing agent delivery system or prodrug, wherein the first member binds to the second member of the ligand-receptor binding pair; and

irradiating at least a portion of the subject with light at a wavelength absorbed by ~~said~~ the photosensitizing agent, wherein ~~said~~ the light is provided by a light source that is external to the ~~subject~~; ~~and wherein~~ subject, wherein ~~said~~ the irradiation is at a relatively low fluence rate that results in the activation of ~~said~~ the photosensitizing agent or prodrug product.

3. (Original) The method of claim 1 or 2, wherein said light source is selected from the group consisting of one or a plurality of: laser diodes, fiber lasers, LEDs, non-laser

light source, cold cathode fluorescent tube, incandescent lights, halogen lights, polymeric luminescent devices, other types of fluorescent lights, discharge lamps, and other electroluminescent devices.

4. (Original) The method of claim 1 or 2, wherein said light is directed through the skin in a direction parallel and lengthwise to the wall of a vascular vessel having the lesion.

5. (Original) The method of claim 3, wherein said laser diode is coupled to an optical fiber, and wherein said optical fiber directs said light lengthwise to the vessel wall having the lesion.

6. (Original) The method of claim 3, wherein said light emitting diode is a light emitting diode strip, and wherein said light emitting diode strip is placed over the skin overlying the lesion.

7. (Original) The method of claim 5, wherein said optical fiber diffuses said light when placed over the vessel wall having the lesion.

8. (Original) The method of claim 5, wherein said light source is a mat comprising a plurality of said optical fiber.

9. (Currently amended) The method of claim 1 or 2, wherein: ~~said~~
~~the photosensitizing agent is selected from the group consisting of: indocyanine~~
~~green; methylene blue; lutetium texaphyrin; toluidine blue; aminolevulinic acid (ALA) and~~
~~any other agent that absorbs light in a range of 600 nm - 1100 nm; and wherein said~~
the agent may be optionally is delivered as a delivery system or as a prodrug, the product thereof resulting in the photosensitizing agent.

10. (Original) The method of claim 1 or 2, wherein said wavelength is from about 600 nm to about 1100 nm.

11. (Original) The method of claim 10, wherein said wavelength is greater than about 700 nm.

12. (Original) The method of claim 11, wherein said light results in a single photon absorption mode by the photosensitizing agent.

13. (Previously presented) The method of claim 9, wherein the ligand is LDL or VLDL.

14. (Original) The method of claim 13, wherein said complex is administered intravenously.

15. (Original) The method of claim 2, wherein said target tissue antigen is selected from the group consisting of: tumor surface antigen; tumor endothelial antigen; non-tumor endothelial antigen; and tumor vessel wall antigen.

16. (Original) The method of claim 2, wherein said ligand-receptor binding pair is selected from the group consisting of: biotin-streptavidin; chemokine-chemokine receptor; growth factor-growth factor receptor; and antigen-antibody.

17. (Currently amended) The method of claim ~~1 or 2~~ 9, wherein said ~~the~~ photosensitizing agent delivery system comprises a liposome delivery system ~~consisting essentially of the photosensitizing agent~~.

18. (Previously presented) The method of claim 1 or 2, wherein said light source is pulse modulated to maximize depth of tissue penetration and minimize heat generation and power consumption.

19. (Currently amended) The method of claim 1 or 2, wherein ~~the~~ a total fluence of the light used for irradiating is between 30 Joules and about 25,000 Joules.

20. (Currently amended) The method of claim 1 or 2, wherein ~~the~~ a total fluence of the light used for irradiating is between about 100 Joules and about 20,000 Joules.

21. (Currently amended) The method of claim 1 or 2, wherein ~~the~~ a total fluence of the light used for irradiating is between about 500 Joules and about 10,000 Joules.

Claims 22 - 24 (Cancelled).

25. (Previously presented) The method of claim 1, wherein the ligand is an antibody or an antibody fragment specific to an antigen selected from the group consisting of tumor surface antigen; tumor endothelial antigen; non-tumor endothelial antigen; tumor vessel wall antigen; neointimal antigens; arterial plaque antigens; and vascular smooth muscle cell antigens.

26. (Previously presented) The method of claim 1, wherein the ligand is heparin or angiotensin II.

27. (Previously presented) The method of claim 2, further comprising administering to the subject a liposome delivery system separately conjugated to the second member of the ligand-receptor binding pair.

28. (New) The method of claim 9, wherein the photosensitizing agent is selected from the group consisting of chlorins, bacteriochlorins, phthalocyanines, porphyrins, purpurins, merocyanines, psoralens, benzoporphyrin derivatives (BPD), porfimer sodium, aminolevulinic acid, indocyanine green, methylene blue, toluidine blue and texaphyrins.